CytRx Corporation in brief
CytRx Corporation is a listed company in the Biotechnology industry, based in Los Angeles, USA. Its last known market value was $26 M (January 2022); there is no current figure. Its shares trade under the symbol CYTR (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About CytRx Corporation
CytRx Corp. is a biopharmaceutical research and development oncology company based in Los Angeles, California.
The CytRx oncology pipeline includes clinical trials involving their lead drug aldoxorubicin. Aldoxorubicin (formerly INNO-206) is a modified form of doxorubicin, the popular anthracycline chemotherapeutic agent known as "red death".
Anthracyclines are a class of drugs that are among the most commonly used agents in the treatment of cancer. Doxorubicin, the first anthracycline to gain approval, has demonstrated efficacy in a wide variety of cancers including breast cancer, lung cancer, sarcomas, and lymphomas. However, doxorubicin is associated with side effects such as myelosuppression, gastrointestinal disorders, mucositis, stomatitis, cumulative cardiotoxicity and extravasation.
From Wikipedia: read the full article · text available under CC BY-SA 4.0
CytRx Corporation timeline
- 1990
- 🔔· approximateInitial public offering on Nasdaq as CYTR
- 1995
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2022
- ✎Renamed LadRx CorpFormerly Cytrx Corp.
Events of CytRx Corporation from Wikidata and SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
Not enough history yet.
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- —
- Price / book
- —
- Free cash flow yield
- —
- Net margin
- —
- Operating margin
- —
- Return on equity
- —
- Liabilities / assets
- 269.0%
- Net debt
- $-38M
- Revenue growth
- +150.0%
- R&D / revenue
- 156.0%
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2024 | — | — | $-4M | $-2M | — |
| Dec 2023 | — | — | $-4M | $0M | — |
| Dec 2022 | — | — | $-5M | $-4M | — |
| Dec 2021 | — | — | $-12M | $-13M | — |
| Dec 2020 | — | — | $-7M | $-7M | — |
| Dec 2019 | — | — | $-8M | $-7M | — |
| Dec 2018 | $0M | +150.0% | $-8M | $-13M | -5084.0% |
| Dec 2017 | $0M | — | $-28M | $-35M | -34990.0% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2024 | $-1M | — | — | $-3.21 | — |
| Dec 2023 | $1M | — | — | $0.68 | — |
| Dec 2022 | $-5M | $0M | $-5M | $-0.11 | — |
| Dec 2021 | $-12M | $0M | $-12M | $-0.35 | — |
| Dec 2020 | $-6M | $0M | $-6M | $-0.19 | — |
| Dec 2019 | $-6M | $0M | $-6M | $-0.22 | — |
| Dec 2018 | $-11M | $0M | $-11M | $-0.41 | — |
| Dec 2017 | $-27M | $0M | $-27M | $-1.46 | — |
Quarterly results
Latest quarter to Mar 2025: revenue —, net income $-1M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Mar 2025.
SEC filings
- Jul 31, 20258-KCurrent reportBankruptcy · Directors or officers changed
- Jun 27, 20258-KCurrent reportOther events
- May 14, 202510-QQuarterly report · period to Mar 2025
- Apr 16, 20258-KCurrent reportDirectors or officers changed
- Mar 28, 202510-KAnnual report · period to Dec 2024
- Nov 14, 202410-QQuarterly report · period to Sep 2024
- Oct 9, 20248-KCurrent reportShareholder vote
- Aug 20, 2024DEF 14AProxy statement
- Aug 14, 202410-QQuarterly report · period to Jun 2024
- Jun 6, 20248-KCurrent reportMaterial agreement · Agreement ended · Other events
- May 15, 202410-QQuarterly report · period to Mar 2024
- Mar 27, 202410-KAnnual report · period to Dec 2023
Official filings of CytRx Corporation with the US Securities and Exchange Commission.
Annual results
- Revenue
- —
- Operating income
- $-4 M
- Net income
- $-2 M
For year ending December-2024 · source: SEC filing
Balance sheet
- Total assets
- $1 M
- Total liabilities
- $2 M
- Total equity
- $-1 M
As of December-2024
Insider trading at CytRx Corporation#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Jennifer K. SimpsonDirector | Grant or award | +25,000 | — | — | 25,000 | Form 4 |
| filed | Earl W. BrienDirector | Option exercise | +150,000 | $0.260 | $39 K | 590,247 | Form 4 |
| filed | Joel K. CaldwellDirector | Option exercise | +450,000 | $0.260 | $117 K | 510,000 | Form 4 |
| filed | Steven A. KriegsmanChief Executive Officer, Director | Option exercise | +3.00 M | $0.260 | $780 K | 4.83 M | Form 4 |
| filed | Louis IgnarroDirector | Option exercise | +700,000 | $0.260 | $182 K | 872,427 | Form 4 |
| filed | Joel K. CaldwellDirector | Shares withheld for tax | -174,627 | $0.670 | $117 K | 335,373 | Form 4 |
| filed | Louis IgnarroDirector | Shares withheld for tax | -271,642 | $0.670 | $182 K | 600,785 | Form 4 |
| filed | Steven A. KriegsmanChief Executive Officer, Director | Shares withheld for tax | -1.16 M | $0.670 | $780 K | 3.67 M | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: CytRx Corporation#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 6-for-1 split in the period to
Bankruptcy filing: (8-K)
| Buybacks, quarter | Fiscal | Spent |
|---|---|---|
| Q4 2015 | Q4 2015 | $0M |
| Q4 2014 | Q4 2014 | $0M |
| Q4 2013 | Q4 2013 | $0M |
| Q3 2013 | Q3 2013 | $0M |
| Q4 2012 | Q4 2013 | $0M |
| Q3 2012 | Q3 2013 | $0M |
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
CytRx Corporation scorecard#
Passes 2 of the 7 checks that could be worked out. Fiscal year 2024.
Valuationnot known
- –P/E below its peers' medianNo market cap.
- –Price to book below its peers' medianNo market cap.
- –Price to sales below its peers' medianNo market cap.
- –Free cash flow yield above 5%No market cap.
- –Earnings yield above the 10-year Treasury yieldNo market cap.
- –The price assumes slower growth than the last three years'No market cap.
Growth1 of 2
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-3.21 vs 0.68Diluted EPS -3.21 in fiscal 2024 against 0.68 the year before (report's currency).
- ✓Net income higher than five years earlier-$2 M-$2 M in fiscal 2024 against -$7 M in 2019.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 2
- ✗Profitable in the newest year-$2 MNet income -$2 M in fiscal 2024.
- ✗Profitable in each of the last five years1 of 5Profitable in 1 of the five years to fiscal 2024.
- –Operating margin above its peers' medianNo operating margin on file.
- –Return on equity above 15%No return on equity (equity missing or negative).
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health0 of 2
- ✗Short-term assets cover short-term liabilities0.4×Current ratio 0.37 at the end of fiscal 2024.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years1 of 3Positive in 1 of the three years to fiscal 2024.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returns1 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✓Share count up no more than 2% in a year1.4%Diluted shares up 1.4% in fiscal 2024.
- –Dividends and buybacks above 3% of the market valueNo market cap.
- –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
CytRx Corporation: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 | FY 2016to Dec 31, 2016 | FY 2015to Dec 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | — | — | — | — | — | — | 0.3+150%100% | 0.1—100% | — | — | |
| Research and development | 0.8+176%— | 0.3—— | — | — | 0.8+98.4%— | 0.4+3.6%— | 0.4−97.5%156% | 16r20−55.9%15848% | 36−17.2%— | 43—— | |
| General and administrative | 2.8−19.5%— | 3.5−22.3%— | 4.5−23.8%— | 6.0−0.6%— | 6.0−19.3%— | 7.4−7.9%— | 8.1−35.4%3232% | 13−21.8%12502% | 16−18.7%— | 20—— | |
| Operating expenses | 3.6−5.2%— | 3.8−16.2%— | 4.6−62.2%— | 12+76.8%— | 6.8−13.1%— | 7.9−7.5%— | 8.5−70.1%3399% | 28—28457% | — | — | |
| Total costs and expenses | — | — | — | — | — | — | — | 33−37.1%32971% | 52−17.2%— | 63—— | |
| Operating income | −3.6—— | −3.8—— | −4.6—— | −12—— | −6.8—— | −7.9—— | −8.2—−3299% | −28r−33—−28357% | −52—— | −63—— | |
| Interest and finance income | — | — | — | — | 0.1−66.1%— | 0.4−1.0%— | 0.4−2.7%142% | 0.4+43.3%366% | 0.3+9.0%— | 0.2—— | |
| Interest expense and finance costs | — | — | — | — | — | — | 1.7−55.2%686% | 3.8+39.1%3831% | 2.8—— | 0—— | |
| Other non-operating income (expense) | — | 0.0—— | −0.0—— | −0.0−168%— | 0.0—— | −0.0−568%— | 0.0−61.8%1.1% | 0.0r−0.0−95.6%7.0% | 0.2+690%— | 0.0—— | |
| Income before tax | — | — | — | −13—— | −6.7—— | −7.5—— | −9.1—−3631% | −30r−35—−30448% | −51—— | −59—— | |
| Income tax | — | — | — | — | 0.00.0%— | 0.0r−0.0—— | −0.0r0.0−200%−0.3% | 0.00.0%0.8% | 0.00.0%— | 0.0—— | |
| Income from continuing operations | — | — | — | — | −6.7—— | −7.5—— | −9.1—−3632% | −30—−30448% | — | — | |
| Income from discontinued operations | — | — | — | — | — | 0.4—— | −3.6r3.6−180%−1454% | 4.5—4538% | — | — | |
| Net income attributable to shareholders | −1.6−497%— | 0.4—— | −4.2—— | −13—— | −6.7—— | −7.2—— | −13—−5085% | −35—−34986% | −51—— | −59—— | |
| Earnings per share, basic | -3.21−572%— | 0.68—— | -0.11—— | -0.35—— | -0.19—— | -0.22—— | -0.41—— | -1.46—— | -3.78r-0.63—— | -5.82r-0.97—— | |
| Earnings per share, diluted | -3.21−572%— | 0.68—— | -0.11—— | -0.35—— | -0.19—— | -0.22—— | -0.41—— | -1.46—— | -3.78r-0.63—— | -5.82r-0.97—— | |
| Shares, weighted average (basic) | 0.5+1.4%— | 0.5+8.4%— | 0.5r43−98.8%— | 38—— | — | — | — | — | — | — | |
| Shares, weighted average (diluted) | 0.5+1.4%— | 0.5+8.4%— | 0.5−98.8%— | 38+8.5%— | 35+4.2%— | 33+7.5%— | 31+28.7%— | 24+78.0%— | 14r81+34.0%— | 10r60—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 0.8−63.3%90.5% | 2.1+50.6%89.7% | 1.4−79.7%61.2% | 6.8−32.3%77.6% | 10−38.0%82.9% | 16−24.5%93.5% | 21−43.0%93.2% | 37r38−33.9%77.6% | 57r57+155%90.4% | 22—33.2% | |
| Receivables | — | — | — | — | — | 0.0−94.9%0.0% | 0.1−98.0%0.6% | 7.5r7.5+3985%15.5% | 0.2−96.0%0.3% | 4.6r4.6—6.9% | |
| Other current assets | 0.1−59.7%9.2% | 0.2−69.5%8.3% | 0.6−52.0%28.0% | 1.3+19.7%15.0% | 1.1+2.6%9.1% | 1.1+16.8%6.2% | 0.9−52.3%4.0% | 1.9−44.3%4.0% | 3.4+44.7%5.5% | 2.4—3.5% | |
| Current assets | 0.8−63.0%99.7% | 2.3+12.9%98.0% | 2.0−75.8%89.2% | 8.3−27.5%94.9% | 11−33.6%94.7% | 17−23.6%99.7% | 23−52.2%98.2% | 47−22.3%97.4% | 61−5.8%96.5% | 64—95.9% | |
| Property, plant and equipment | 0.0−85.1%0.1% | 0.0−63.8%0.3% | 0.0−43.4%0.8% | 0.0−17.5%0.4% | 0.0−7.3%0.3% | 0.0−3.2%0.2% | 0.0−38.0%0.2% | 0.1r1.0−96.4%0.1% | 2.0+33.5%3.1% | 1.5—2.2% | |
| Right-of-use (leased) assets | — | 0.0−85.4%1.4% | 0.2−45.4%9.6% | 0.4−31.6%4.6% | 0.6—4.8% | — | — | — | — | — | |
| Goodwill | — | — | — | — | — | — | — | 0.20.0%0.4% | 0.20.0%0.3% | 0.2—0.3% | |
| Total assets | 0.8−63.6%100% | 2.3+2.7%100% | 2.2−74.3%100% | 8.7−27.6%100% | 12−30.1%100% | 17−24.7%100% | 23−52.6%100% | 48−23.0%100% | 63−6.3%100% | 67—100% | |
| Accounts payable | 1.1−12.1%126% | 1.2+23.2%52.1% | 1.0−33.6%43.4% | 1.5+4.9%16.9% | 1.4+57.9%11.6% | 0.9−28.1%5.1% | 1.2−69.6%5.4% | 4.1r4.1−36.5%8.4% | 6.4−20.5%10.2% | 8.1—12.0% | |
| Debt due within a year | — | — | — | — | — | — | — | 11+93.4%21.9% | 5.5—8.7% | 0—0.0% | |
| Current liabilities | 2.3+2.7%269% | 2.2+0.6%95.3% | 2.2−41.4%97.4% | 3.7+34.6%42.8% | 2.8+35.3%23.0% | 2.1−20.0%11.9% | 2.6−91.5%11.2% | 30+54.8%62.5% | 20−15.0%31.1% | 23—34.2% | |
| Long-term debt | — | — | — | — | — | — | — | 0−100%0.0% | 18—29.4% | 0—0.0% | |
| Lease liabilities (non-current) | — | — | 0.0−84.5%1.5% | 0.2−47.9%2.5% | 0.4—3.4% | — | — | — | — | — | |
| Total liabilities | — | 2.2−0.9%95.3% | 2.2−43.8%98.9% | 4.0+23.9%45.3% | 3.2+55.6%26.4% | 2.1−20.0%11.9% | 2.6−91.5%11.2% | 30−20.5%62.5% | 38+65.6%60.5% | 23—34.2% | |
| Retained earnings | −490—−58379% | −489—−21167% | −489—−21757% | −484—−5547% | −471—−3903% | −464—−2689% | −457—−1993% | −451—−933% | −416—−663% | −365—−545% | |
| Shareholders' equity | −1.4−1422%−169% | 0.1—4.7% | −1.3−275%−58.7% | 0.8−91.5%8.6% | 8.9−41.7%73.6% | 15−25.3%88.1% | 20+12.2%88.8% | 18−26.8%37.5% | 25−43.8%39.5% | 44—65.8% | |
| Total liabilities and equity | 0.8−63.6%100% | 2.3+2.7%100% | 2.2−74.3%100% | 8.7−27.6%100% | 12−30.1%100% | 17−24.7%100% | 23−52.6%100% | 48−23.0%100% | 63−6.3%100% | 67—100% | |
| Shares outstanding | 0.50.0%— | 0.5+9.9%— | 0.5r45−98.8%— | 39+6.3%— | 36+8.5%— | 340.0%— | 34+20.0%— | 28+51.1%— | 19r111−72.1%— | 66—— | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | 0.0−51.7%— | 0.0−21.1%— | 0.0+7.3%— | 0.0−51.9%— | 0.0+40.6%— | 0.0−29.8%— | 0.0−72.5%11.8% | 0.1r0.6−80.1%107% | 0.5+68.9%— | 0.3—— | |
| Share-based compensation | 0.1—— | — | 0.0—— | — | 0.3−83.7%— | 2.0+23.8%— | 1.6−47.9%649% | 3.1r3.3−53.8%3112% | 6.7−8.8%— | 7.4—— | |
| Cash from operating activities | −1.3−229%— | 1.0—— | −4.8—— | −12—— | −6.1—— | −5.7—— | −11—−4347% | −27r−27—−27101% | −50—— | −48—— | |
| Capital expenditure | — | — | −0.0—— | −0.0—— | −0.0—— | −0.0—— | −0.0—−4.6% | −0.1—−135% | −1.0—— | −0.3—— | |
| Cash from investing activities | — | — | −0.0—— | −0.0—— | −0.0−105%— | 0.5—— | −0.0—−4.6% | −0.1−100%−135% | 34+232%— | 10—— | |
| Debt issued | — | — | — | — | — | — | — | 0−100%0.0% | 24—— | 0—— | |
| Debt repaid | — | — | — | — | — | — | −10.0—−3995% | −15—−15014% | 0—— | 0—— | |
| Shares bought back | — | — | — | — | — | — | — | — | 0—— | 0—— | |
| Cash from financing activities | — | −0.3—— | −0.6−106%— | 9.1+23187%— | 0.0—— | — | −5.2−165%−2098% | 8.0−84.1%8016% | 51+84.6%— | 27—— | |
| Change in cash | −1.3−289%— | 0.7—— | −5.4—— | −3.2—— | −6.1—— | −5.2—— | −16—−6450% | −19r−19−155%−19220% | 35—— | −10.0—— | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Mar 31, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 | Q3 FY2023to Sep 30, 2023 | Q2 FY2023to Jun 30, 2023 | Q1 FY2023to Mar 31, 2023 | Q4 FY2022to Dec 31, 2022 | Q3 FY2022to Sep 30, 2022 | Q2 FY2022to Jun 30, 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Research and development | 0.8—— | 0.0−4.9%— | 0.1*−45.6%— | 0.0−69.5%— | 0.6—— | 0.0—— | 0.3*—— | 0.0—— | — | — | — | — | — | |
| General and administrative | 2.7−16.0%— | 0.7−13.8%— | 0.5*−14.3%— | 0.8−0.3%— | 0.7−31.4%— | 0.8−25.8%— | 0.6*−35.3%— | 0.8−29.3%— | 1.0−11.1%— | 1.1—— | 0.9*—— | 1.2—— | 1.1—— | |
| Operating expenses | — | — | — | — | — | — | — | — | 1.0−11.1%— | 1.1—— | 1.0*—— | 1.2—— | 1.1—— | |
| Operating income | −3.5—— | −0.7—— | −0.7*—— | −0.8—— | −1.3—— | −0.8—— | −0.9*—— | −0.8—— | −1.0—— | −1.1—— | −1.0*—— | −1.2—— | −1.1—— | |
| Other non-operating income (expense) | — | — | — | — | — | — | 0.0*—— | 0.0−71.2%— | 0.0—— | 0.0—— | −0.0*—— | 0.0—— | −0.0—— | |
| Net income attributable to shareholders | −2.5−250%— | −0.7−485%— | 0.3*—— | −0.8—— | −1.3−141%— | 0.2—— | −0.9*—— | −0.8—— | 3.1—— | −1.1—— | −0.9*—— | −1.2—— | −0.8—— | |
| Earnings per share, basic | — | -1.45−482%— | — | -1.67—— | -2.59−140%— | 0.38—— | — | -1.65—— | 6.45—— | -0.03—— | — | -2.78r-0.03—— | -2.25r-0.02—— | |
| Earnings per share, diluted | — | -1.45−482%— | — | -1.67—— | -2.59−140%— | 0.38—— | — | -1.65—— | 6.45—— | -0.03—— | — | -2.78—— | -2.25—— | |
| Shares, weighted average (basic) | 0.50.0%— | 0.50.0%— | — | 0.50.0%— | 0.5+1.4%— | 0.5+7.4%— | — | 0.5+9.9%— | 0.5+10.2%— | 0.5r46—— | — | 0.5r45—— | 0.4r44—— | |
| Shares, weighted average (diluted) | 0.50.0%— | 0.50.0%— | — | 0.50.0%— | 0.5+1.4%— | 0.5+7.4%— | — | 0.5+9.9%— | 0.5+10.2%— | 0.5—— | — | 0.5—— | 0.4—— | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 0.2—79.6% | 0.2−90.0%79.6% | 0.8−63.3%90.5% | 0.1−98.0%77.0% | 0.8−77.3%91.3% | 2.1+240%92.9% | 2.1+50.6%89.7% | 2.9−2.7%95.7% | 3.6−12.4%90.5% | 0.6—49.3% | 1.4—61.2% | 3.0—89.2% | 4.1—81.7% | |
| Other current assets | 0.1—19.7% | 0.1−66.0%19.7% | 0.1−59.7%9.2% | 0.0−62.6%18.2% | 0.1−68.9%8.1% | 0.2−64.9%6.8% | 0.2−69.5%8.3% | 0.0−49.2%1.2% | 0.2−51.2%5.9% | 0.4—34.9% | 0.6—28.0% | 0.1—2.1% | 0.5—9.5% | |
| Current assets | 0.3—99.3% | 0.3−88.3%99.3% | 0.8−63.0%99.7% | 0.1−97.6%95.2% | 0.9−76.8%99.5% | 2.2+114%99.7% | 2.3+12.9%98.0% | 3.0−3.8%96.9% | 3.8−18.2%96.3% | 1.0—84.2% | 2.0—89.2% | 3.1—91.4% | 4.7—93.2% | |
| Property, plant and equipment | 0.0—0.1% | 0.0−92.4%0.1% | 0.0−85.1%0.1% | 0.0−78.4%2.8% | 0.0−74.3%0.4% | 0.0−70.2%0.2% | 0.0−63.8%0.3% | 0.0−56.6%0.3% | 0.0−51.5%0.3% | 0.0—1.3% | 0.0—0.8% | 0.0—0.7% | 0.0—0.5% | |
| Right-of-use (leased) assets | — | — | — | — | — | — | 0.0−85.4%1.4% | 0.1−70.0%2.6% | 0.1−59.2%3.1% | 0.2—13.9% | 0.2—9.6% | 0.3—7.8% | 0.3—6.1% | |
| Total assets | 0.3—100% | 0.3−88.3%100% | 0.8−63.6%100% | 0.1−97.6%100% | 0.9−77.6%100% | 2.2+80.5%100% | 2.3+2.7%100% | 3.1−9.3%100% | 4.0−20.9%100% | 1.2—100% | 2.2—100% | 3.4—100% | 5.0—100% | |
| Accounts payable | 1.1—424% | 1.1+23.5%424% | 1.1−12.1%126% | 0.8−19.4%1070% | 0.8−20.7%93.2% | 0.9−20.8%40.2% | 1.2+23.2%52.1% | 1.0+9.3%32.2% | 1.1−13.2%26.4% | 1.1—91.5% | 1.0—43.4% | 0.9—26.7% | 1.2—24.1% | |
| Current liabilities | 2.4—921% | 2.4+27.7%921% | 2.3+2.7%269% | 1.8−12.9%2459% | 1.8−17.0%204% | 1.9−20.1%84.5% | 2.2+0.6%95.3% | 2.1−7.0%68.5% | 2.2−14.0%55.3% | 2.3—191% | 2.2—97.4% | 2.3—66.9% | 2.6—50.8% | |
| Lease liabilities (non-current) | — | — | — | — | — | — | — | — | — | — | 0.0—1.5% | 0.1—2.5% | 0.2—3.8% | |
| Total liabilities | — | — | — | — | — | — | 2.2−0.9%95.3% | 2.1—68.5% | — | — | 2.2—98.9% | — | — | |
| Retained earnings | −491—−188722% | −491—−188722% | −490—−58379% | −490—−659406% | −490—−54771% | −488—−21984% | −489—−21167% | −488—−15907% | −487—−12225% | −490—−39822% | −489—−21757% | −488—−14436% | −487—−9670% | |
| Shareholders' equity | −2.1—−821% | −2.1−718%−821% | −1.4−1422%−169% | −1.8−282%−2359% | −0.9−152%−104% | 0.3—15.5% | 0.1—4.7% | 1.0—31.5% | 1.8+89.4%44.7% | −1.8—−147% | −1.3—−58.7% | −0.3—−9.1% | 0.9—18.7% | |
| Total liabilities and equity | 0.3—100% | 0.3−88.3%100% | 0.8−63.6%100% | 0.1−97.6%100% | 0.9−77.6%100% | 2.2+80.5%100% | 2.3+2.7%100% | 3.1−9.3%100% | 4.0−20.9%100% | 1.2—100% | 2.2—100% | 3.4—100% | 5.0—100% | |
| Shares outstanding | 0.5—— | 0.50.0%— | 0.50.0%— | 0.50.0%— | 0.50.0%— | 0.5−98.9%— | 0.5+9.9%— | 0.5−98.9%— | 0.5−98.9%— | 47—— | 0.5r45—— | 45—— | 45—— | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | 0.0−60.8%— | 0.0−69.0%— | 0.0*−63.3%— | 0.0*−60.6%— | 0.0*−52.7%— | 0.0−30.4%— | 0.0*−21.2%— | 0.0*−21.3%— | 0.0*−21.2%— | 0.0—— | 0.0*—— | 0.0*—— | 0.0*—— | |
| Share-based compensation | 0.0—— | 0.0−92.3%— | 0.0*—— | 0.0*—— | 0.0*—— | 0.1—— | — | 0*−100%— | 0*−100%— | 0—— | 0.0*—— | 0.0*—— | 0.0*—— | |
| Cash from operating activities | −1.9−209%— | −0.6—— | 0.7*—— | −0.8*—— | −1.2*−138%— | −0.0—— | −0.9*—— | −0.7*—— | 3.2*—— | −0.7—— | −1.6*—— | −1.0*—— | −0.8*—— | |
| Capital expenditure | — | — | — | — | — | — | — | — | — | — | 0*—— | 0*—— | 0*—— | |
| Cash from investing activities | — | — | — | — | — | — | — | — | — | — | 0*—— | 0*—— | 0*—— | |
| Cash from financing activities | — | — | — | — | — | — | 0*—— | 0*—— | −0.3*—— | −0.1—— | −0.1*—— | −0.1*—— | −0.2*—— | |
| Change in cash | −1.9−227%— | −0.6—— | 0.7*—— | −0.8*—— | −1.2*−142%— | −0.0—— | −0.9*—— | −0.7*—— | 3.0*—— | −0.8—— | −1.6*—— | −1.1*—— | −1.0*—— | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Mar 31, 2025. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Events at CytRx Corporation#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Warning signs in the last three years
- Bankruptcy or receivershipDebt called earlyFiling
Bankruptcy or receivership 1 · Debt called early 1 · Acquisition or sale completed 1 · Directors and officers 8 · Material agreement 2 · Agreement ended 1 · Shareholder rights changed 4 · Bylaws or fiscal year changed 5 · Shareholder vote 4
| Filed | What happened | Filing |
|---|---|---|
| Bankruptcy or receivershipDebt called earlyDirectors and officers | 8-K | |
| Directors and officers | 8-K | |
| Shareholder vote | 8-K | |
| Material agreementAgreement ended | 8-K | |
| Directors and officers | 8-K/A | |
| Directors and officersShareholder rights changedBylaws or fiscal year changedShareholder vote | 8-K | |
| Acquisition or sale completedMaterial agreement | 8-K | |
| Shareholder rights changedBylaws or fiscal year changed | 8-K | |
| Directors and officers | 8-K | |
| Bylaws or fiscal year changed | 8-K | |
| Shareholder vote | 8-K | |
| Directors and officers | 8-K | |
| Shareholder rights changedBylaws or fiscal year changed | 8-K | |
| Shareholder rights changedBylaws or fiscal year changedShareholder vote | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Jul 31, 2025
Acquisitions and funding#
Private share sales · funding history
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
From US state WARN notices and SEC 8-K restructuring filings, newest first.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2007 | · | · | · | · | · | · | · | · | · | · | · | · | — |
| Announced | People | Kind | Where | Source |
|---|---|---|---|---|
| Not stated | Restructuring planSEC 8-K | Company-wide plan | Filing |
Source: State WARN notices and SEC 8-K item 2.05
How CytRx Corporation compares in Biotechnology
- Revenue growth150.0% · higher than 87% of 438
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| CytRx Corporation🇺🇸 | $26 M | — | — | +150.0% |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Novo Nordisk A/S$203.2 B
- Vertex Pharmaceuticals Incorporated$134.3 B
- Moderna, Inc.$90.1 B
- Regeneron Pharmaceuticals, Inc.$84.1 B
- Argenx SE$52.8 B
- CSL Limited$51.6 B
Sources and freshness
- Market cap:
- Jan 7, 2022 (last known)
- Annual results:
- For year ending December-2024
- Balance sheet:
- As of December-2024
- Profile updated:
- Nov 16, 2026
Figures from SEC filing, Wikidata, Wikipedia, value.today research, GLEIF register; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at CytRx Corporation? Verify and update this profile — free
Show CytRx Corporation's ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.